alanine has been researched along with Neuroendocrine Tumors in 3 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Neuroendocrine Tumors: Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Preclinical trials of a mouse model of pancreatic neuroendocrine tumors (PNET) were conducted to determine whether dual FGF/VEGF pathway inhibition with brivanib can improve first-line efficacy in comparison with VEGF inhibitors lacking fibroblast growth factor (FGF)-inhibitory activity and to characterize second-line brivanib activity before and after the onset of evasive resistance to VEGF-selective therapy." | 7.77 | Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. ( Allen, E; Hanahan, D; Walters, IB, 2011) |
| "Preclinical trials of a mouse model of pancreatic neuroendocrine tumors (PNET) were conducted to determine whether dual FGF/VEGF pathway inhibition with brivanib can improve first-line efficacy in comparison with VEGF inhibitors lacking fibroblast growth factor (FGF)-inhibitory activity and to characterize second-line brivanib activity before and after the onset of evasive resistance to VEGF-selective therapy." | 3.77 | Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. ( Allen, E; Hanahan, D; Walters, IB, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, E | 1 |
| Walters, IB | 1 |
| Hanahan, D | 1 |
| Yao, JC | 1 |
| Phan, A | 1 |
| Vitale, L | 1 |
| Frabetti, F | 1 |
| Huntsman, SA | 1 |
| Canaider, S | 1 |
| Casadei, R | 1 |
| Lenzi, L | 1 |
| Facchin, F | 1 |
| Carinci, P | 1 |
| Zannotti, M | 1 |
| Coppola, D | 1 |
| Strippoli, P | 1 |
3 other studies available for alanine and Neuroendocrine Tumors
| Article | Year |
|---|---|
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
Topics: Alanine; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesul | 2011 |
Overcoming antiangiogenic resistance.
Topics: Alanine; Animals; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Triazines | 2011 |
Sequence, "subtle" alternative splicing and expression of the CYYR1 (cysteine/tyrosine-rich 1) mRNA in human neuroendocrine tumors.
Topics: Adult; Aged; Alanine; Alternative Splicing; Amino Acid Sequence; Animals; Base Sequence; Codon; Dige | 2007 |